A Safety and Pharmacokinetics Study of Niraparib Plus Androgen Receptor-Targeted Therapy (Apalutamide or Abiraterone Acetate Plus Prednisone) in Men With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Safety and Pharmacokinetics Study of Niraparib Plus Androgen Receptor-Targeted Therapy (Apalutamide or Abiraterone Acetate Plus Prednisone) in Men With Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Niraparib (Primary) ; Prednisone (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms BEDIVERE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 17 Aug 2017 Planned primary completion date changed from 17 Jul 2017 to 7 May 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 21 Apr 2017 Planned number of patients changed from 30 to 60.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top